Chemical biology

We are developing strategies for interrogating the “organ on a chip” platform with innovative drugs that affect cellular and systemic energy metabolism as well as differentiation (pre-clinical, early stage clinical, and registered drugs). In the second phase of the project, we aim to use organoids derived from human disease cohorts or carrying specific engineered mutations for drug testing.

Contributing research group

• The Krauss Group